Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of June 2025, with a specific reporting date of June 6, 2025. The document serves as a notification of transactions by Persons Discharging Managerial Responsibilities (PDMRs) in compliance with the UK Market Abuse Regulation. Haleon operates as a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report is strictly a regulatory disclosure regarding insider shareholding changes and does not contain financial performance data.
Material Changes
The material change disclosed is an acquisition of Ordinary Shares by Tamara Rogers, the Chief Marketing Officer and a PDMR. The transaction was executed on June 5, 2025, on the London Stock Exchange (XLON). The shares were acquired via a dividend reinvestment plan at a price of £4.01403 per share. The filing text does not provide a clear value for the total volume of shares acquired.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on strategy, or specific risk factors. The document focuses solely on the statutory disclosure of the PDMR transaction.
Key Facts for Investor Verification
- Transaction Type: Acquisition of Ordinary Shares via dividend reinvestment.
- Executive Involved: Tamara Rogers, Chief Marketing Officer (PDMR).
- Transaction Date: June 5, 2025.
- Transaction Price: £4.01403 per share.
- Exchange: London Stock Exchange (XLON).
- Share Class: Ordinary Shares of £0.01 each (ISIN: GB00BMX86B70).